Zanubrutinib joins the CLL treatment buffet
Mené sur 590 patients atteints d'une leucémie lymphoïde chronique ou d'un lymphome à petits lymphocytes (durée médiane de suivi : 26,2 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du zanubritinib par rapport à un traitement combinant bendamustine et rituximab
The advent of targeted therapies has transformed the treatment landscape of chronic lymphocytic leukaemia (CLL). Although chemoimmunotherapy constituted the standard of care in earlier decades, Bruton tyrosine kinase (BTK) inhibitors (ibrutinib and acalabrutinib), BCL2 inhibitors (venetoclax), and combinations thereof are currently the cornerstone of CLL management. With the intention of minimising off-target adverse effects, new BTK inhibitors, such as zanubrutinib and acalabrutinib, have been developed and approved for the treatment of several B-cell malignancies. In the field of relapsed or refractory CLL, zanubrutinib has shown a favourable efficacy and toxicity profile compared with ibrutinib.